Global Cancer/Tumor Profiling Market Size study & Forecast, by Cancer Type, Biomarker Type, Technology, Technique, Application and Regional Forecasts 2025-2035

Description

The Global Cancer/Tumor Profiling Market is valued at approximately USD 10.73 billion in 2024 and is anticipated to grow at a CAGR of more than 12.50% over the forecast period 2025-2035. Cancer/Tumor Profiling refers to the process of analyzing genetic mutations, biomarker expressions, and molecular signatures to better understand the nature of cancer and its progression. By providing a personalized view of each tumor, profiling helps physicians identify the most effective treatment pathways, predict drug response, and monitor patient outcomes with higher precision. This rapidly advancing field is propelled by the rising prevalence of cancer worldwide, growing adoption of precision medicine, and increasing investments in next-generation sequencing technologies. Moreover, the integration of advanced bioinformatics platforms is further accelerating the pace at which clinicians and researchers can decode the molecular complexity of cancer.

The surge in global cancer incidence has intensified the demand for profiling solutions as stakeholders look to shift away from a one-size-fits-all approach to oncology care. According to the World Health Organization, cancer accounted for nearly 10 million deaths in 2022, with breast, lung, and colorectal cancers ranking among the most common. These alarming figures underscore the urgency for better diagnostic, prognostic, and therapeutic tools. Tumor profiling has consequently emerged as a cornerstone in personalized medicine, enabling early detection and guiding targeted treatment. The rapid progress of molecular diagnostic technologies, particularly next-generation sequencing and mass spectrometry, has lowered costs and improved efficiency, thus making profiling more accessible across hospitals, research institutes, and diagnostic centers. However, high testing costs, coupled with limited infrastructure in underdeveloped regions, still pose challenges to widespread adoption.

The detailed segments and sub-segments included in the report are:

By Cancer Type:

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Other Cancer

By Biomarker Type:

Genomic Biomarker
Protein Biomarker

By Technology:

Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others

By Technique:

Genomics
Proteomics
Metabolomics
Epigenetics

By Application:

Research
Biomarker Discovery
Personalized Medicine
Clinical Application
Diagnostics
Prognostics
Screening
Treatment
Monitoring

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa
Breast Cancer is Expected to Dominate the Market
Breast cancer profiling is projected to dominate the cancer/tumor profiling market during the forecast period. This dominance stems from the rising global prevalence of breast cancer, extensive screening initiatives, and the rapid integration of genomic and proteomic profiling techniques in breast cancer diagnostics. Advancements in biomarker-based assays and targeted therapies have elevated the demand for comprehensive profiling to identify tumor-specific drivers. Furthermore, increasing awareness campaigns, government-supported early detection programs, and an upsurge in funding for breast cancer research have reinforced its position as the largest revenue-generating segment in this domain.
Next-Generation Sequencing Leads in Revenue Contribution
By technology, Next-Generation Sequencing (NGS) continues to be the leading contributor to the market's revenue. Its capability to simultaneously analyze millions of DNA fragments offers unparalleled speed and accuracy in decoding tumor heterogeneity. While immunoassays and PCR techniques remain critical for routine applications due to their affordability and accessibility, NGS has become indispensable in advanced oncology research and clinical trials. Additionally, the technology's declining costs, coupled with increasing adoption in both developed and developing healthcare systems, are propelling its growth further. The picture is twofold: NGS dominates the market in revenue terms, whereas complementary technologies like immunoassays are expected to maintain strong adoption in cost-sensitive settings.
The key regions considered for the Global Cancer/Tumor Profiling Market study include Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. North America held the largest share in 2025, supported by advanced healthcare infrastructure, a high prevalence of cancer, and strong R&D investments by biotechnology firms. The presence of leading market players, favorable reimbursement policies, and rapid adoption of advanced diagnostic platforms further boost the region's dominance. Meanwhile, Asia Pacific is projected to be the fastest-growing region, driven by the rise in cancer incidence, growing awareness of precision medicine, and expanding healthcare infrastructure in countries like China and India. Government support for genomic research and increasing collaborations between regional hospitals and global biotech firms are expected to accelerate demand for tumor profiling across APAC.

Major market players included in this report are:

Illumina, Inc.
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
QIAGEN N.V.
Agilent Technologies, Inc.
PerkinElmer, Inc.
Guardant Health, Inc.
Exact Sciences Corporation
Caris Life Sciences
Nanostring Technologies, Inc.
NeoGenomics Laboratories, Inc.
HTG Molecular Diagnostics, Inc.
Foundation Medicine, Inc.
Genomic Health, Inc.
Eurofins Scientific

Global Cancer/Tumor Profiling Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent to up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of the competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Cancer/Tumor Profiling Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. key Findings

Chapter 3. Global Cancer/Tumor Profiling Market Forces Analysis

3.1. Market Forces Shaping The Global Cancer/Tumor Profiling Market (2024-2035)
3.2. Drivers
- 3.2.1. The rising prevalence of cancer worldwide
- 3.2.2. Growing adoption of precision medicine
3.3. Restraints
- 3.3.1. Limited infrastructure in underdeveloped regions
3.4. Opportunities
- 3.4.1. The integration of advanced bioinformatics platforms

Chapter 4. Global Spacer Fluid Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Cancer/Tumor Profiling Market Size & Forecasts by Cancer Type 2025-2035

5.1. Market Overview
5.2. Global Cancer/Tumor Profiling Market Performance - Potential Analysis (2025)
5.3. Breast Cancer
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Lung Cancer
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035\
5.5. Colorectal Cancer
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035
5.6. Prostate Cancer
- 5.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.6.2. Market size analysis, by region, 2025-2035
5.7. Melanoma Cancer
- 5.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.7.2. Market size analysis, by region, 2025-2035
5.8. Other Cancer
- 5.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.8.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Cancer/Tumor Profiling Market Size & Forecasts by Biomarker Type 2025-2035

6.1. Market Overview
6.2. Global Cancer/Tumor Profiling Market Performance - Potential Analysis (2025)
6.3. Genomic Biomarker
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Protein Biomarker
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Cancer/Tumor Profiling Market Size & Forecasts by Technology 2025-2035

7.1. Market Overview
7.2. Global Cancer/Tumor Profiling Market Performance - Potential Analysis (2025)
7.3. Immunoassays
- 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.3.2. Market size analysis, by region, 2025-2035
7.4. Next-Generation Sequencing
- 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.4.2. Market size analysis, by region, 2025-2035
7.5. Polymerase Chain Reaction
- 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.5.2. Market size analysis, by region, 2025-2035
7.6. Mass Spectrometry
- 7.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.6.2. Market size analysis, by region, 2025-2035
7.7. In-Situ Hybridization
- 7.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.7.2. Market size analysis, by region, 2025-2035
7.8. Microarrays
- 7.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.8.2. Market size analysis, by region, 2025-2035
7.9. Others
- 7.9.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.9.2. Market size analysis, by region, 2025-2035

Chapter 8. Global Cancer/Tumor Profiling Market Size & Forecasts by Technique 2025-2035

8.1. Market Overview
8.2. Global Cancer/Tumor Profiling Market Performance - Potential Analysis (2025)
8.3. Genomics
- 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.3.2. Market size analysis, by region, 2025-2035
8.4. Proteomics
- 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.4.2. Market size analysis, by region, 2025-2035
8.5. Metabolomics
- 8.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.5.2. Market size analysis, by region, 2025-2035
8.6. Epigentics
- 8.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.6.2. Market size analysis, by region, 2025-2035

Chapter 9. Global Cancer/Tumor Profiling Market Size & Forecasts by Technology 2025-2035

9.1. Market Overview
9.2. Global Cancer/Tumor Profiling Market Performance - Potential Analysis (2025)
9.3. Research
- 9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.3.2. Market size analysis, by region, 2025-2035
9.4. Biomarker Discovery
- 9.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.4.2. Market size analysis, by region, 2025-2035
9.5. Personalized Medicine
- 9.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.5.2. Market size analysis, by region, 2025-2035
9.6. Clinical Application
- 9.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.6.2. Market size analysis, by region, 2025-2035
9.7. Diagnostics
- 9.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.7.2. Market size analysis, by region, 2025-2035
9.8. Prognostics
- 9.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.8.2. Market size analysis, by region, 2025-2035
9.9. Screening
- 9.9.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.9.2. Market size analysis, by region, 2025-2035
9.10. Treatment
- 9.10.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.10.2. Market size analysis, by region, 2025-2035
9.11. Monitoring
- 9.11.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.11.2. Market size analysis, by region, 2025-2035

Chapter 10. Global Cancer/Tumor Profiling Market Size & Forecasts by Region 2025-2035

10.1. Growth Cancer/Tumor Profiling Market, Regional Market Snapshot
10.2. Top Leading & Emerging Countries
10.3. North America Cancer/Tumor Profiling Market
- 10.3.1. U.S. Cancer/Tumor Profiling Market
  - 10.3.1.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.3.1.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.3.1.3. Technology breakdown size & forecasts, 2025-2035
  - 10.3.1.4. Technique breakdown size & forecasts, 2025-2035
  - 10.3.1.5. Application breakdown size & forecasts, 2025-2035
- 10.3.2. Canada Cancer/Tumor Profiling Market
  - 10.3.2.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.3.2.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.3.2.3. Technology breakdown size & forecasts, 2025-2035
  - 10.3.2.4. Technique breakdown size & forecasts, 2025-2035
  - 10.3.2.5. Application breakdown size & forecasts, 2025-2035
10.4. Europe Cancer/Tumor Profiling Market
- 10.4.1. UK Cancer/Tumor Profiling Market
  - 10.4.1.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.4.1.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.4.1.3. Technology breakdown size & forecasts, 2025-2035
  - 10.4.1.4. Technique breakdown size & forecasts, 2025-2035
  - 10.4.1.5. Application breakdown size & forecasts, 2025-2035
- 10.4.2. Germany Cancer/Tumor Profiling Market
  - 10.4.2.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.4.2.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.4.2.3. Technology breakdown size & forecasts, 2025-2035
  - 10.4.2.4. Technique breakdown size & forecasts, 2025-2035
  - 10.4.2.5. Application breakdown size & forecasts, 2025-2035
- 10.4.3. France Cancer/Tumor Profiling Market
  - 10.4.3.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.4.3.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.4.3.3. Technology breakdown size & forecasts, 2025-2035
  - 10.4.3.4. Technique breakdown size & forecasts, 2025-2035
  - 10.4.3.5. Application breakdown size & forecasts, 2025-2035
- 10.4.4. Spain Cancer/Tumor Profiling Market
  - 10.4.4.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.4.4.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.4.4.3. Technology breakdown size & forecasts, 2025-2035
  - 10.4.4.4. Technique breakdown size & forecasts, 2025-2035
  - 10.4.4.5. Application breakdown size & forecasts, 2025-2035
- 10.4.5. Italy Cancer/Tumor Profiling Market
  - 10.4.5.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.4.5.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.4.5.3. Technology breakdown size & forecasts, 2025-2035
  - 10.4.5.4. Technique breakdown size & forecasts, 2025-2035
  - 10.4.5.5. Application breakdown size & forecasts, 2025-2035
- 10.4.6. Rest of Europe Cancer/Tumor Profiling Market
  - 10.4.6.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.4.6.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.4.6.3. Technology breakdown size & forecasts, 2025-2035
  - 10.4.6.4. Technique breakdown size & forecasts, 2025-2035
  - 10.4.6.5. Application breakdown size & forecasts, 2025-2035
10.5. Asia Pacific Cancer/Tumor Profiling Market
- 10.5.1. China Cancer/Tumor Profiling Market
  - 10.5.1.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.5.1.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.5.1.3. Technology breakdown size & forecasts, 2025-2035
  - 10.5.1.4. Technique breakdown size & forecasts, 2025-2035
  - 10.5.1.5. Application breakdown size & forecasts, 2025-2035
- 10.5.2. India Cancer/Tumor Profiling Market
  - 10.5.2.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.5.2.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.5.2.3. Technology breakdown size & forecasts, 2025-2035
  - 10.5.2.4. Technique breakdown size & forecasts, 2025-2035
  - 10.5.2.5. Application breakdown size & forecasts, 2025-2035
- 10.5.3. Japan Cancer/Tumor Profiling Market
  - 10.5.3.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.5.3.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.5.3.3. Technology breakdown size & forecasts, 2025-2035
  - 10.5.3.4. Technique breakdown size & forecasts, 2025-2035
  - 10.5.3.5. Application breakdown size & forecasts, 2025-2035
- 10.5.4. Australia Cancer/Tumor Profiling Market
  - 10.5.4.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.5.4.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.5.4.3. Technology breakdown size & forecasts, 2025-2035
  - 10.5.4.4. Technique breakdown size & forecasts, 2025-2035
  - 10.5.4.5. Application breakdown size & forecasts, 2025-2035
- 10.5.5. South Korea Cancer/Tumor Profiling Market
  - 10.5.5.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.5.5.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.5.5.3. Technology breakdown size & forecasts, 2025-2035
  - 10.5.5.4. Technique breakdown size & forecasts, 2025-2035
  - 10.5.5.5. Application breakdown size & forecasts, 2025-2035
- 10.5.6. Rest of APAC Cancer/Tumor Profiling Market
  - 10.5.6.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.5.6.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.5.6.3. Technology breakdown size & forecasts, 2025-2035
  - 10.5.6.4. Technique breakdown size & forecasts, 2025-2035
  - 10.5.6.5. Application breakdown size & forecasts, 2025-2035
10.6. Latin America Cancer/Tumor Profiling Market
- 10.6.1. Brazil Cancer/Tumor Profiling Market
  - 10.6.1.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.6.1.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.6.1.3. Technology breakdown size & forecasts, 2025-2035
  - 10.6.1.4. Technique breakdown size & forecasts, 2025-2035
  - 10.6.1.5. Application breakdown size & forecasts, 2025-2035
- 10.6.2. Mexico Cancer/Tumor Profiling Market
  - 10.6.2.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.6.2.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.6.2.3. Technology breakdown size & forecasts, 2025-2035
  - 10.6.2.4. Technique breakdown size & forecasts, 2025-2035
  - 10.6.2.5. Application breakdown size & forecasts, 2025-2035
10.7. Middle East and Africa Cancer/Tumor Profiling Market
- 10.7.1. UAE Cancer/Tumor Profiling Market
  - 10.7.1.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.7.1.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.7.1.3. Technology breakdown size & forecasts, 2025-2035
  - 10.7.1.4. Technique breakdown size & forecasts, 2025-2035
  - 10.7.1.5. Application breakdown size & forecasts, 2025-2035
- 10.7.2. Saudi Arabia (KSA) Cancer/Tumor Profiling Market
  - 10.7.2.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.7.2.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.7.2.3. Technology breakdown size & forecasts, 2025-2035
  - 10.7.2.4. Technique breakdown size & forecasts, 2025-2035
  - 10.7.2.5. Application breakdown size & forecasts, 2025-2035
- 10.7.3. South Africa Cancer/Tumor Profiling Market
  - 10.7.3.1. Cancer Type breakdown size & forecasts, 2025-2035
  - 10.7.3.2. Biomarker Type breakdown size & forecasts, 2025-2035
  - 10.7.3.3. Technology breakdown size & forecasts, 2025-2035
  - 10.7.3.4. Technique breakdown size & forecasts, 2025-2035
  - 10.7.3.5. Application breakdown size & forecasts, 2025-2035

Chapter 11. Competitive Intelligence

11.1. Top Market Strategies
11.2. Illumina, Inc.
- 11.2.1. Company Overview
- 11.2.2. Key Executives
- 11.2.3. Company Snapshot
- 11.2.4. Financial Performance (Subject to Data Availability)
- 11.2.5. Product/Services Port
- 11.2.6. Recent Development
- 11.2.7. Market Strategies
- 11.2.8. SWOT Analysis
11.3. F. Hoffmann-La Roche Ltd.
11.4. Thermo Fisher Scientific, Inc.
11.5. QIAGEN N.V.
11.6. Agilent Technologies, Inc.
11.7. PerkinElmer, Inc.
11.8. Guardant Health, Inc.
11.9. Exact Sciences Corporation
11.10. Caris Life Sciences
11.11. Nanostring Technologies, Inc.
11.12. NeoGenomics Laboratories, Inc.
11.13. HTG Molecular Diagnostics, Inc.
11.14. Foundation Medicine, Inc.
11.15. Genomic Health, Inc.
11.16. Eurofins Scientific